Boston Scientific Corporation $BSX Stock Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its holdings in Boston Scientific Corporation (NYSE:BSX) by 14.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,040,055 shares of the medical equipment provider’s stock after selling 353,025 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Boston Scientific were worth $89,056,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Parallel Advisors LLC grew its stake in Boston Scientific by 15.0% in the third quarter. Parallel Advisors LLC now owns 17,639 shares of the medical equipment provider’s stock worth $770,000 after purchasing an additional 2,301 shares in the last quarter. Guidance Capital Inc. lifted its holdings in shares of Boston Scientific by 82.8% in the 3rd quarter. Guidance Capital Inc. now owns 11,573 shares of the medical equipment provider’s stock worth $513,000 after buying an additional 5,243 shares during the period. United Advisor Group LLC purchased a new stake in shares of Boston Scientific in the 3rd quarter worth $218,000. May Hill Capital LLC grew its position in shares of Boston Scientific by 1.8% during the 3rd quarter. May Hill Capital LLC now owns 37,526 shares of the medical equipment provider’s stock worth $1,638,000 after buying an additional 651 shares in the last quarter. Finally, Waycross Partners LLC increased its position in Boston Scientific by 13.7% during the 3rd quarter. Waycross Partners LLC now owns 308,313 shares of the medical equipment provider’s stock valued at $13,458,000 after purchasing an additional 37,083 shares during the period. 89.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on BSX. Evercore reduced their price objective on shares of Boston Scientific from $65.00 to $52.00 and set an “outperform” rating for the company in a research note on Wednesday, October 7th. Rothschild & Co Redburn cut their price target on Boston Scientific from $106.00 to $78.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Argus lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, July 31st. Robert W. Baird upped their price objective on Boston Scientific from $50.00 to $51.00 and gave the stock an “outperform” rating in a research note on Thursday, October 29th. Finally, Truist Financial cut their target price on Boston Scientific from $57.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $61.43.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $44.00 on Tuesday. The company has a market capitalization of $63.78 billion, a PE ratio of 18.64, a price-to-earnings-growth ratio of 1.36 and a beta of 0.60. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.74 and a current ratio of 1.36. The company’s fifty day moving average price is $44.26 and its 200 day moving average price is $55.46. Boston Scientific Corporation has a 1 year low of $39.57 and a 1 year high of $105.65.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting analysts’ consensus estimates of $0.73. The business had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The business’s revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.75 earnings per share. On average, research analysts predict that Boston Scientific Corporation will post 3.17 earnings per share for the current year.

About Boston Scientific

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts.

Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Boston Scientific serves healthcare providers and patients around the world.